These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34201664)

  • 1. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment.
    Vidal S; Puig L; Carrascosa-Carrillo JM; González-Cantero Á; Ruiz-Carrascosa JC; Velasco-Pastor AM
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brodalumab: A new way to inhibit IL-17 in psoriasis.
    Facheris P; Valenti M; Pavia G; Guanziroli E; Narcisi A; Borroni RG; Costanzo A
    Dermatol Ther; 2020 May; 33(3):e13403. PubMed ID: 32285564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
    Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
    Front Immunol; 2020; 11():1894. PubMed ID: 32973785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.
    Johansen C; Usher PA; Kjellerup RB; Lundsgaard D; Iversen L; Kragballe K
    Br J Dermatol; 2009 Feb; 160(2):319-24. PubMed ID: 19016708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.
    Plachouri KM; Chourdakis V; Georgiou S
    Drugs Today (Barc); 2019 Sep; 55(9):587-593. PubMed ID: 31584575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brodalumab for the treatment of psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1255-1271. PubMed ID: 27718760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SEF/IL-17R (SEFIR) is not enough: an extended SEFIR domain is required for il-17RA-mediated signal transduction.
    Onishi RM; Park SJ; Hanel W; Ho AW; Maitra A; Gaffen SL
    J Biol Chem; 2010 Oct; 285(43):32751-32759. PubMed ID: 20729198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of IL-17 in psoriasis.
    Malakouti M; Brown GE; Wang E; Koo J; Levin EC
    J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interleukin-17 treatment of psoriasis.
    Jinna S; Strober B
    J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.
    Brembilla NC; Senra L; Boehncke WH
    Front Immunol; 2018; 9():1682. PubMed ID: 30127781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
    Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
    Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bimekizumab for the Treatment of Psoriasis.
    Freitas E; Blauvelt A; Torres T
    Drugs; 2021 Oct; 81(15):1751-1762. PubMed ID: 34623614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis.
    Green L; Weinberg JM; Menter A; Soung J; Lain E; Jacobson A
    J Drugs Dermatol; 2020 Feb; 19(2):138-143. PubMed ID: 32129957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixekizumab for treatment of psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2015 Apr; 11(4):435-42. PubMed ID: 25748485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
    Chiricozzi A
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
    Puig L
    Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex.
    Wright JF; Bennett F; Li B; Brooks J; Luxenberg DP; Whitters MJ; Tomkinson KN; Fitz LJ; Wolfman NM; Collins M; Dunussi-Joannopoulos K; Chatterjee-Kishore M; Carreno BM
    J Immunol; 2008 Aug; 181(4):2799-805. PubMed ID: 18684971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.